Healtcare Prostate Cancer Therapeutics Market | Page 2

therapies are expected to be predominately approved in castration-resistant patients, and to compete
with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as
adjuvants to established therapies. For instance, there is a strong pipeline of products such as
Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473
(Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the
market in the near future. However, high cost and side effects associated with drugs can restraint the
market growth.
Rising implications associated with prostate cancer are expected to affect the prostate cancer
therapeutics market
Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older
men. According to National Cancer Registry Ireland, 2011, median age at prostate cancer diagnosis
in Ireland was 67 years with 38.9% of cases being diagnosed in men and 21.3% in men 75+ years.
Median age at death was 80 with 70.3% of deaths occurring in men 75+ years. Moreover,
Supportive initiatives undertaken by key players in collaboration with various governments to
create more awareness of clinical symptoms about prostate cancer and availability of screening &
diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting
in early detection are also the factors which expected to boost the prostate cancer therapeutics
market. However, high cost associated with drugs, and poor reimbursement of treatment cost may
affect the prostate cancer therapeutics negatively.
The global prostate cancer therapeutics market was valued at US$ 8,191.11 million in 2016 and is
expected to witness a CAGR of 7.5% during the forecast period (2017 – 2025).
For More Information @ https://www.coherentmarketinsights.com/market-insight/prostate-
cancer-therapeutics-market-1257
Endeavor to introduce highly effective therapies for prostate cancer would support the
market growth
Many research organizations and universities are investing in research for the development of
therapeutic products for the treatment of such tumors. For instance, some pipeline products which
are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura
University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the
near future. Furthermore, many products that are about to face patent expiry during the forecast
period will also contribute in the growth of the generic prostate cancer therapeutics market. Many
pharmaceutical companies are also focusing on introducing their respective drugs in different
countries to boost the sales of their products. For instance, in December, 2016, Sanofi’s prostate
cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate
cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within
NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern
Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this
vulnerable group of patients.
Global Key Players:
Key players operating in the prostate cancer therapeutics market include Johnson & Johnson,
Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation
(Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
Detailed Segmentation:
•Global Prostate Cancer Therapeutics Market, By Drug Type: